S&P Futures
3,783.50 -37.75 (-0.99%) Dow Futures
30,762.00 -237.00 (-0.76%) Nasdaq Futures
11,545.75 -145.25 (-1.24%) Russell 2000 Futures
1,703.20 -18.20 (-1.06%) Crude Oil
109.31 -0.47 (-0.43%) Gold
1,813.70 -3.80 (-0.21%)
Axsome Therapeutics, Inc. (AXSM)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 37.96 |
| Open | 38.40 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 2200 |
| Day's Range | 35.92 - 39.80 |
| 52 Week Range | 19.38 - 68.74 |
| Volume | |
| Avg. Volume | 1,580,996 |
| Market Cap | 1.375B |
| Beta (5Y Monthly) | 2.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.35 |
| Earnings Date | Feb 28, 2022 - Mar 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 81.21 |
- Benzinga
What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder
Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea (OSA). SVB Leerink says its view on Sunosi has not changed. Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) struggled to differentiate Sunosi in a generic market, and SVB remains skeptical that Axsome will be able to do much better. Related: Axsome Acquires Sleep Disorder Drug From Jazz Pharma, Expanding Its
- GlobeNewswire
Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is hosting a virtual event today at 9:00 AM EDT to provide investors an update on Sunosi® (solriamfetol). Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepin
- Barrons.com
Axsome Therapeutics Stock Soars on Proposed FDA Labeling for Depression Drug
Cowen analyst Joseph Thome said the disclosure is "an encouraging sign and hopefully an important step toward a potential near-term FDA approval" of Axsome's drug for major depressive disorder.
